DR-70: A Beacon from Detection to Prognosis in Canine Oncology

Shang Jyh Kao[1], Chiao Hsu Ke[2], Chen Si Lin[2] and Yu Shan Wang[2,3]*

[1]Division of Chest Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

[2]Department of Veterinary Medicine, National Taiwan University, Taipei, 10617, Taiwan, ROC

[3]Uni-Pharma Co-Ltd., 11494, Taipei, Taiwan

Review Article

ABSTRACT

This comprehensive review delves into the DR-70 biomarker's role in canine cancer detection, its potential in prognosis, and monitoring treatment responses. Initially identified as a promising diagnostic tool, DR-70 has demonstrated significant accuracy and sensitivity in identifying various canine tumors. Beyond detection, recent studies have begun exploring its capabilities as a prognostic tool, examining its correlation with cancer stages, types, and expected outcomes. These investigations suggest that DR-70 levels may vary with different cancer types and stages, potentially indicating disease progression and treatment efficacy. Additionally, the review compares DR-70's effectiveness with other biomarkers like C-reactive protein, circulating tumor DNA, and another promising biomarker, nucleosome, discussing the benefits of a multi-biomarker approach for a more comprehensive understanding of canine cancers. Despite the promise, challenges in specificity, sensitivity, and the influence of concurrent diseases pose limitations to DR-70's clinical utility. The review emphasizes the need for further research, larger cohorts, and advanced technological approaches to enhance the biomarker's reliability and application. It concludes by highlighting the promising future of DR-70 in veterinary oncology, where it could significantly improve prognosis, tailor treatment strategies, and ultimately enhance the management and outcomes of oncological conditions in dogs. The collective efforts in research and technological advancements are crucial in realizing the full potential of DR-70 as a multifaceted tool in the fight against canine cancer.

INTRODUCTION

Cancer is a challenging disease that affects dogs and their owners deeply [1]. Early detection and continuous monitoring of this disease were crucial for effective treatment and improved survival rates [2]. In recent years, the discovery and application of reliable biomarkers have revolutionized cancer care, including in veterinary medicine. This article explored the DR-70 biomarker, which was initially identified as a promising diagnostic tool for canine neoplasms, and its potential in prognosis and treatment monitoring [3].

The discovery and analysis of the DR-70 biomarker was a breakthrough in the field of veterinary oncology. Studies indicated that DR-70 levels were significantly elevated in dogs with different types of tumors as opposed to healthy canines. This degradation product of fibrinogen-fibrin demonstrated impressive accuracy and sensitivity, making it a valuable diagnostic tool for identifying cancer in dogs [3]. The initial findings not only underscored the biomarker's effectiveness in detecting neoplasms but also paved the way for its potential wider applications in the field of oncology.

LITERATURE REVIEW

Biomarkers, which are biological molecules found in blood, other body fluids, or tissues, can indicate normal or abnormal processes, conditions, or diseases within the body. In the realm of cancer care, biomarkers serve a range of important purposes. They can aid in the early detection and diagnosis of cancer, help to predict the aggressiveness of a cancer, and enable crucial monitoring of the body's response to treatment [4]. One such biomarker, DR-70, can offer insight into a cancer's behavior and response to treatment, allowing for personalized treatment plans and real-time adjustments to therapeutic strategies [3,5-12].

We reviewed the latest research on DR-70 and its connection to canine cancer. DR-70 shows promise as a multi-faceted biomarker for predicting and monitoring cancer treatment in veterinary oncology. This summary presents recent research and discoveries on DR-70 and how it could shape the future of cancer care for dogs.

Correlation between DR-70 levels and cancer stages, types, or expected outcomes

The field of veterinary oncology was constantly advancing, and the DR-70 biomarker had emerged as an invaluable tool for detecting and predicting cancer outcomes [13]. Understanding the course and prognosis of cancer was critical for effective treatment and managing the disease. These studies delved into recent research and clinical trials that explored the potential of DR-70 beyond its diagnostic capabilities, including its role in prognosis, correlation with different cancer stages and types, and ability to predict cancer aggressiveness and survival rates [5-12,14]. These studies underscored the significance of DR-70 as a biomarker for cancer prognosis and emphasized the need for ongoing research in this field, which may also have implications for canine oncology.

Recent research has begun to shift the focus from using DR-70 solely as a diagnostic marker to understanding its prognostic capabilities. A series of studies have investigated how DR-70 levels change in response to cancer progression and treatment in human [6,8-10,12]. For instance, a longitudinal study involving with hepatocellular carcinoma monitored DR-70 levels over several months, correlating the changes with disease progression, remission and recurrence [9]. Another trial focused on gastric cancer undergoing chemotherapy, observing how DR-

70 levels responded to treatment and correlated these responses with survival times [12]. These studies suggest that DR-70 may have a significant role in not just detecting cancer, but also in providing a prognosis.

Understanding the relationship between DR-70 levels and cancer specifics is crucial for its application in prognosis. Research indicates that DR- 70 levels may vary significantly with different types and stages of cancer. For instance, some studies have found that higher levels of DR-70 are often associated with more advanced stages of cancer and may indicate a poorer prognosis [6-10,12]. Additionally, certain types of cancers, such as those that are highly metastatic or particularly aggressive, may exhibit distinctly elevated DR-70 levels [9]. DR-70 concentration changes may predict canine neoplasms. High DR-70 levels in plasma may shorten survival and indicate treatment effectiveness. Veterinarians can estimate cancer progression and prognosis by correlating DR-70 levels with specific characteristics. Results not published yet.

Navigating the future of DR-70: A comparative and forward-looking analysis in canine oncology

DR-70 is a significant biomarker for predicting and monitoring cancer in veterinary oncology. We compared it to other biomarkers, explored the potential of combining them, and discussed future opportunities for using DR- 70 beyond cancer detection. DR-70's effectiveness and utility need to be considered in the broader context of available and emerging biomarkers.

Traditional markers like C-Reactive Protein (CRP) and newer ones like circulating tumor DNA (ctDNA) have their own roles and capabilities in detecting and monitoring canine cancers [15-18]. While CRP is a general marker for inflammation and can be elevated in various diseases including cancer, ctDNA provides a more specific insight into the genetic makeup of the tumor [17,18]. DR-70's unique advantage lies in its high specificity and sensitivity, particularly in certain types of cancers [3]. However, when compared to ctDNA, which can provide information on tumor mutations and potential treatment targets, DR-70's data might be less specific to individualized treatment strategies. Understanding these differences helps in selecting the right marker or combination of markers for each patient's situation. The use of multiple biomarkers, including DR-70, can potentially provide a more comprehensive picture of the cancer's presence, type, progression, and response to treatment. This synergistic approach can leverage the strengths of each marker to cover the weaknesses of others. For instance, while DR-70 might indicate the presence and severity of cancer, ctDNA could help in understanding the specific mutations and guide targeted therapy. Studies exploring these combinations are crucial as they can lead to more accurate diagnoses, better prognostic assessments, and more personalized treatment plans.

Advancing canine oncology: A comparative review of DR-70 and plasma nucleosome concentrations as cancer biomarkers

In the world of veterinary oncology, the quest to find reliable and accurate biomarkers for early cancer detection in dogs has led to the exploration of a couple of potential candidates. Plasma nucleosome concentrations have gained much attention recently, in addition to DR-70 [19-23]. Both biomarkers have been studied extensively in human medicine and have demonstrated significant promise in bridging the gap between human and veterinary oncology [5,10,19,24]. These biomarkers offer a new level of insight into the early detection and management of canine cancers, which may ultimately improve the prognosis and quality of life for our furry friends.

The research conducted on DR-70, a diagnostic tool, has demonstrated its potential as an efficient and reliable method with impressive sensitivity and specificity levels. With 84.03% sensitivity and 78.33% specificity, DR-70 is a

versatile tool in veterinary practice, capable of detecting a wide range of tumors without being influenced by other factors such as tumor type, sex, age, or body weight [3]. DR-70's ability to detect metastatic mast cell tumors and oral malignant melanoma specifically makes it an invaluable tool in early tumor detection and treatment strategies for dogs [3]. However, the study acknowledges the need for further research to fully understand DR-70's effectiveness and specificity, especially in dogs with non-neoplastic diseases. Overall, the study highlights DR-70's potential as a robust and versatile diagnostic tool that could significantly enhance early tumor detection and improve treatment outcomes for dogs [3].

The study investigated the use of plasma nucleosome concentrations as a biomarker, which has the ability to detect cancer with a specificity of 97%, though it is less sensitive, at 49.8%. Plasma nucleosome concentrations are particularly effective in detecting hematopoietic tumors, such as lymphoma and hemangiosarcoma, while being less effective in detecting local tumors like soft tissue sarcomas. The study involved a larger cohort of 528 dogs with cancer and 134 healthy dogs, making it a reliable dataset for analysis and comparison. This highlights the in-depth understanding of specific cancer types that can be obtained through the use of plasma nucleosome concentrations [21].

When it comes to cancer detection tests, it is essential to choose the right one that can accurately detect cancer while minimizing the risk of false positives or negatives. DR-70 is a widely used test that provides a balanced approach between sensitivity and specificity. It can detect cancer in its early stages, making it a versatile tool for detecting cancer in a universal context. Furthermore, DR-70 can identify different types of cancer, making it a valuable tool for cancer diagnosis. Plasma nucleosome concentrations, on the other hand, are a more specific test that can provide valuable insights into particular types of cancers. This test is less sensitive overall, but it can accurately detect specific cancer types, making it an ideal choice for targeted cancer screening.

The choice between DR-70 and plasma nucleosome concentrations depends on the clinical scenario. If the goal is to detect cancer early and in a wide range of cancers, DR-70 may be the preferred option. If the goal is to detect a specific type of cancer, or if reducing false positives or negatives is a priority, plasma nucleosome concentrations may be the better option. The findings of both studies highlight the critical role of continued research and development in the field of canine cancer detection. DR-70, a biomarker with broad potential, and plasma nucleosome concentrations, which offer specific benefits, suggest that a diagnostic approach combining multiple modalities may provide the most comprehensive tool for identifying cancer in dogs. To achieve this, future research should concentrate on integrating these biomarkers with traditional diagnostic methods, such as imaging and biopsy, to enhance the accuracy and reliability of canine cancer detection. Such an approach could lead to earlier detection, more effective treatment, and improved outcomes for dogs with cancer.

In brief, DR-70 and plasma nucleosome concentrations are two distinct pathways that show great potential in detecting cancer in dogs. These two biomarkers provide critical insights into canine oncology and set the stage for future innovations in veterinary medicine. Through continuous research and development, these biomarkers could revolutionize cancer detection and treatment in dogs, enabling earlier diagnosis and more effective treatments. Ultimately, the advancement of these biomarkers has the potential to significantly improve the quality of life and lifespan of our beloved four-legged friends.

Challenges and limitations

Despite its potential, the extension of DR-70 from detection to prognosis and monitoring comes with challenges. One primary concern is the specificity and sensitivity of DR-70 in various cancer stages and types. While it has shown promise, false positives or negatives can have significant implications for treatment decisions. The

biomarker's reliability can also be affected by concurrent diseases or conditions that might influence DR-70 levels. Understanding and mitigating these factors are crucial for the effective use of DR-70 in clinical settings.

Future directions

The future of DR-70 in veterinary oncology is a path paved with ongoing research and technological advancements. Further studies, particularly those involving larger and more diverse cohorts, are essential for validating DR-70's utility in prognosis and treatment monitoring. Multi-center trials can help establish standardized protocols and provide a broader understanding of its application across different populations. Additionally, advancements in technology could enhance the sensitivity and specificity of DR-70 measurements, and new methodologies might uncover additional aspects of its prognostic and monitoring capabilities.

CONCLUSION

DR-70 stands at a promising juncture in the field of veterinary oncology. Its potential, when considered alongside other biomarkers, opens new avenues for the prognosis and monitoring of canine cancers. However, realizing this potential fully requires overcoming significant challenges and continuing to push the boundaries of research and technology. As we move forward, the combined efforts of veterinarians, researchers, and technologists will be key in shaping a future where DR-70 and other biomarkers provide a more nuanced, effective, and personalized approach to cancer care in dogs.

REFERENCES

1. Sarver AL, et al. Increased risk of cancer in dogs and humans: a consequence of recent extension of lifespan beyond evolutionarily-determined limitations? Aging Cancer. 2022;3:3-19.

2. Colombe P, et al. Blood biomarkers for canine cancer, from human to veterinary oncology. Vet Comp Oncol. 2022;20:767-777.

3. Ke CH, et al. Increased plasma DR-70 (fibrinogen-fibrin degradation products) concentrations as a diagnostic biomarker in dogs with neoplasms. J Vet Intern Med. 2023;37:2391-2401.

4. Manne U, et al. Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today. 2005;10:965-976.

5. Kerber A, et al. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther. 2004;20:983-987.

6. Li X, et al. Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue. Br J Oral Maxillofac Surg. 2005;43:513-515.

7. Schaffrath M, et al. Ovarian carcinoma: Clinical validity by simultaneous determination of fibrin degradation products with the DR-70™ immunoassay and CA-125. Geburtshilfe und Frauenheilkunde. 2006;66:68-75.

8. Small-Howard AL, et al. Advantages of the AMDL-ELISA DR-70 (FDP) assay over Carcinoembryonic Antigen (CEA) for monitoring colorectal cancer patients. J Immunoassay Immunochem. 2010;31:131-147.

9. Lin SZ, et al. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:547-552.

10. Yesil A, et al. Prognostic significance of DR-70 levels in dysplastic colorectal polyps. Gastroenterol Res Pract. 2013;2013275392.

11. So HJ, et al. Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer. Biomed Rep. 2014;2:737-742.

12. Hung YP, et al. The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. J Chin Med Assoc. 2018;81:593-598.

13. Sakai M, et al. Fibrin/fibrinogen degradation products are associated with tumor stage and prognosis in patients undergoing resection of esophageal cancer. Anticancer Res. 2021;41:4523.

14. Wu DF, et al. Sensitivity and specificity of Dr-70™ lung cancer immunoassay. Anal Lett. 1999;32:1351-1362.

15. Hart PC, et al. C-reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol. 2020;11595835.

16. Tecles F, et al. Serum acute phase protein concentrations in female dogs with mammary tumors. J Vet Diagn. 2009;21:214-219.

17. Favaro PF, et al. Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions. Sci Rep. 2022;12:6337.

18. Stejskal P, et al. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Molecular Cancer. 2023;22:15.

19. Wilson-Robles H, et al. Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies. Plos One. 2023;18:e0281796.

20. Wilson-Robles H, et al. Evaluation of nucleosome concentrations in healthy dogs and dogs with cancer. PLOS ONE. 2020;15:e0236228.

21. Wilson-Robles HM, et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res. 2022;18:329.

22. Dolan C, et al. Characterizing circulating nucleosomes in the plasma of dogs with lymphoma. BMC Vet Res. 2021;17:276.

23. Wilson-Robles H, et al. Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma. BMC Vet Res. 2021;17:231.

24. Bauden M, et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics. 2015;7106.